(Press-News.org) Late-breaking abstract featured at ASCO 2025
ROCHESTER, Minn. — Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have lagged.
Now, new research led by Mayo Clinic Comprehensive Cancer Center found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer — and with a specific genetic makeup called deficient DNA mismatch repair (dMMR) — was associated with a 50% reduction in cancer recurrence and death compared to chemotherapy alone. Approximately 15% of people diagnosed with colon cancer exhibit dMMR and, to date, these tumors appear less sensitive to chemotherapy. The results of the multi-center study were presented during a plenary session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
"The findings from our study represent a major advance in the adjuvant treatment of dMMR stage 3 colon cancer and will now change the treatment for this type of cancer," says oncologist Frank Sinicrope, M.D., who led the study. "It's extremely rewarding to be able to offer our patients a new treatment regimen that can reduce the risk of recurrence and improve their chances of survival."
Until now, the standard treatment after surgery for any stage 3 colon cancer has been chemotherapy. However, the researchers note that approximately 30% of patients experience cancer recurrence despite this treatment.
The clinical trial enrolled 712 patients with dMMR stage 3 colon cancer that had been surgically removed and who had cancer cells in their lymph nodes. The immunotherapy given in this study was an immune checkpoint inhibitor, known as atezolizumab, which activates one's immune system to attack and kill cancer cells, which are responsible for cancer recurrence and spread. The patients — who lived in the U.S. and Germany — received chemotherapy for six months along with immunotherapy and then continued with immunotherapy alone for another six months.
Dr. Sinicrope and others previously studied patients with colon cancer whose cells are unable to repair errors during DNA replication that create a nucleotide mismatch, a condition called dMMR. They noted that these patients' tumors showed a striking increase in inflammatory cells within the tumor, including those that express the target of immune checkpoint inhibitors. This sparked the idea of using immune checkpoint inhibitors to make the immune cells more effective in attacking and killing the cancer cells.
Based on the data from this study, Dr. Sinicrope recommends this combination of immunotherapy and chemotherapy treatment to be the new standard treatment for stage 3 deficient mismatch repair colon cancer. The research team plans to approach the National Comprehensive Cancer Network, a nonprofit organization consisting of 33 leading cancer centers, including Mayo Clinic, with this recommendation.
The study included patients with Lynch syndrome, the most common form of hereditary colon cancer, as these patients can have tumors that show deficient mismatch repair (dMMR).
"We're changing the paradigm in colon cancer treatment. By using immunotherapy at earlier stages of disease, we are achieving meaningful benefits for our patients," says Dr. Sinicrope.
Review the abstract for a complete list of authors, disclosures and funding.
###
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.
About Mayo Clinic Comprehensive Cancer Center
Designated as a comprehensive cancer center by the National Cancer Institute, Mayo Clinic Comprehensive Cancer Center is defining the cancer center of the future, focused on delivering the world's most exceptional patient-centered cancer care for everyone. At Mayo Clinic Comprehensive Cancer Center, a culture of innovation and collaboration is driving research breakthroughs in cancer detection, prevention and treatment to change lives.
END
Immunotherapy boosts chemotherapy in combating stage 3 colon cancer
2025-06-01
ELSE PRESS RELEASES FROM THIS DATE:
AI deciphers plant DNA: language models set to transform genomics and agriculture
2025-06-01
By leveraging the structural parallels between genomic sequences and natural language, these AI-driven models can decode complex genetic information, offering unprecedented insights into plant biology. This advancement holds promise for accelerating crop improvement, enhancing biodiversity conservation, and bolstering food security in the face of global challenges.
Traditionally, plant genomics has grappled with the intricacies of vast and complex datasets, often limited by the specificity of traditional machine learning models and the scarcity of annotated ...
Endophytic fungi from halophyte Sesuvium portulacastrum enhance maize growth and salt tolerance
2025-06-01
This research provides key insights into how microbial inoculants can offer a cost-effective, eco-friendly strategy to enhance crop resilience in saline soils.
Soil salinization is a major global challenge that severely impacts agricultural productivity, with over 3% of the Earth’s terrestrial surface affected. It threatens food security by causing osmotic, ionic, and oxidative stress, which can reduce crop yields by more than 50%. Traditional remediation methods, such as physical and chemical interventions, are often prohibitively expensive. However, ...
Quality of kids’ diets linked with dad’s eating habits as a teen
2025-05-31
While moms have traditionally gotten much of the focus when it comes to children’s eating habits, a new study highlights the importance of dads in shaping a child’s relationship with food. According to the study, young children were more likely to consume the recommended amount of fruits and vegetables if their father ate a healthier diet during his teen years.
The study is based on data from 669 men who answered questionnaires about their eating habits during adolescence and then, years later, provided information about their attitudes and behaviors surrounding their children’s diet.
“Our ...
Alliance trial shows dual immunotherapy improves progression-free survival in advanced squamous cell skin cancer
2025-05-31
May 31, 2025 — A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free survival (PFS) compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma (cSCC). The results, presented as an oral abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, and published in the Journal of Clinical Oncology, suggest a promising new approach for patients with this aggressive form of skin cancer.
“These results show that combining immune checkpoint inhibition targeting the PD-1: PD-L1 pathway ...
Insights from immunotherapy trial inform new approaches to treating advanced skin cancer
2025-05-31
In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had almost four times longer median progression-free survival compared to patients who received avelumab alone, according to the results of a phase 2 trial presented today at the American Society of Clinical Oncology (ASCO) meeting and concurrently published in the Journal of Clinical Oncology.
“It is both an honor and humbling to develop clinical trials ...
Genome breakthrough reveals secrets behind rapid growth and invasiveness of tropical vine Merremia boisiana
2025-05-31
Merremia boisiana, a member of the Convolvulaceae family, a fast-growing vine native to tropical rainforests and known for its vibrant golden flowers and astonishing climbing ability, grows at speeds exceeding 12 cm per day, often overwhelming native vegetation and disrupting forest ecosystems. Despite its ecological importance and genetic proximity to economically vital crops like sweet potato (Ipomoea batatas), little was known about its genomic makeup until now.
A study (DOI:10.48130/tp-0025-0007) published in Tropical Plants on 24 March 2025 by Fei Chen and Wenquan Wang’s team, Hainan University, marks a significant leap ...
Transforming the certification process of 3D-printed critical components
2025-05-30
At present, it takes an average of 18 months for a supercomputer to evaluate a single 3D part and accurately predict its lifespan or expected date of failure. The Defense Advanced Research Projects Agency (DARPA)’s Structures Uniquely Resolved to Guarantee Endurance (SURGE) program has tasked grantees with compressing this evaluation time to three days and significantly simplifying the process so that it can be performed on a laptop computer.
Four members of the Texas A&M University faculty have responded to that ...
UC Davis clinical trial shows biomarkers hold clue in treating aggressive prostate cancer
2025-05-30
Many men with aggressive prostate cancer can experience a high rate of recurrence despite treatment.
A new Phase 2 clinical trial at UC Davis Comprehensive Cancer Center unveiled clues as to why these patients are doing poorly and may offer hope in the form of targeted therapy.
The findings will be presented at the annual American Society of Clinical Oncology (ASCO) conference on June 3 in Chicago. .
Pilot trial sheds new clues ...
UT Health San Antonio researchers discover new links between heart disease and dementia
2025-05-30
SAN ANTONIO, May 30, 2025 – People who are at higher risk for heart disease also seem more likely to develop dementia.
And research led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has discovered new associations between various lipid, or fat, levels in the blood and the risk of developing Alzheimer’s disease, the most common cause of dementia worldwide.
The findings mean that using blood lipid profiles could help better understand, predict and possibly even prevent the disease in the future.
In more than 800 older adults who were part of the long-running Framingham Heart Study, the researchers ...
AADOCR announces new SCADA/Dentsply Sirona Research Award
2025-05-30
Alexandria, VA – AADOCR and the Student Competition for Advancing Dental Research and its Application (SCADA) Alumni Association are pleased to announce the AADOCR SCADA/Dentsply Sirona Research Award.
The new award was created to support dentist-scientists, including SCADA program alumni, in their research careers. The award’s immediate goal is to support early-stage dentist-scientists such as post-doctoral scholars and pre-tenure faculty members, with a long-term objective of increasing the number of successfully funded dentist-scientists ...